Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Antimicrobial resistance

European Medicines Agency to reconsider colistin advice

The European Medicines Agency (EMA) is looking at whether its advice about the use of  colistin in animals, especially pigs, needs to be updated following a request from the European Commission (EC).

Colistin has traditionally been used as a last-resort antibiotic for the treatment of some bacterial infections in humans. But it is also approved in veterinary medicine for the treatment of infected animals, especially pigs and those in contact with them. It is not approved for prophylactic use.

The request by the EC to revise the veterinary guidelines follows the recent discovery of a colistin-resistant gene – the MCR-1 gene. The gene was first detected in bacteria that were isolated from pigs, pork and chicken products and from a small number of humans in South China. The gene has since appeared in the European Union, including the UK.

An EMA expert group — the Antimicrobial Advice Ad Hoc Expert Group (AMEG), which drew up the original 2013 advice, is being reconvened to reconsider its position following the discovery of the MCR-1 gene.

The group will review the new evidence and whether its original advice needs to change. It will take into account the importance of colistin to human and veterinary medicine, the impact of resistance, the availability of alternative treatments and the effectiveness of possible risk-management measures to protect human and animal health.

The review is expected to take six months. Any changes will have to be approved by the EMA before recommendations are made to the EC. 

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2016.20200461

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • BNF and BNF for Children

    BNF and BNF for Children

    Now available as a 1 year print subscription to both the BNF and BNFC, ensuring you have the latest medicines information as it publishes and at a greatly reduced price.

    £138.50Buy now
  • BNF and BNF for Children

    BNF and BNF for Children

    Now available as a 2 year print subscription to both the BNF and BNFC, ensuring you have the latest medicines information as it publishes and at a greatly reduced price.

    £262.50Buy now
  • International Research in Healthcare

    International Research in Healthcare

    Guidance for students or researchers undertaking a multi-centre research project in health services, medicines use and professional practice.

    £38.00Buy now
  • Drugs in Use

    Drugs in Use

    Optimise drug therapy for your patients. These case studies help you bridge the gap between theoretical medicines knowledge and practical applications.

    £43.00Buy now
  • Pharmaceutical Toxicology

    Pharmaceutical Toxicology

    Explains the methodology and requirements of pre-clinical safety assessments of new medicines. Includes registration requirements and pharmacovigilance.

    £40.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.